Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.35 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 4/20 | 0.33 |
| ▸ | BID | P55957 | 3/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.33 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.33 |
| ▸ | BAK1 | Q16611 | 2/20 | 0.33 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | KAT2A | Q92830 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726891 | 0.81 | MEN1 (0.41) | HTR6AGTR1AGTR2ATMSMN1; SMN2 | |
| SCHEMBL725696 | 0.74 | SMN1; SMN2 (0.39) | HTR6AGTR1AGTR2ATMSMN1; SMN2 | |
| SCHEMBL725665 | 0.69 | PTGDR2 (0.35) | BIDMCL1BCL2L1BAK1 | |
| SCHEMBL726112 | 0.67 | TSHR (0.52) | AGTR1AGTR2ATMSMN1; SMN2KMT2A | |
| SCHEMBL11143339 | 0.66 | LIPG (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL11137516 | 0.66 | LIPG (0.51) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL29577175 | 0.66 | HTR6 (0.69) | HTR6DRD2HTR7 | |
| SCHEMBL28050271 | 0.66 | LIPG (0.50) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL906430 | 0.65 | LIPG (0.53) | BIDMCL1BCL2L1BAK1KAT8 | |
| SCHEMBL906515 | 0.65 | LIPG (0.53) | BIDMCL1BCL2L1BAK1KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR6 4243/4885AGTR1 2987/4885AGTR2 3340/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HTR6 4243/4885AGTR1 2987/4885AGTR2 3340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.